首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

1890943

腫瘤血液檢測市場按生物標記類型、技術、臨床應用、癌症類型、最終用戶和地區分類

Tumor Blood Testing Market, By Biomarker Type, By Technology, By Clinical Application, By Cancer Type, By End User, By Geography

出版日期: 2025年11月08日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年腫瘤血液學檢測市場規模預計為 93.4 億美元，預計到 2032 年將達到 238.1 億美元，2025 年至 2032 年的複合年成長率為 14.3%。

報告內容		報告詳情
基準年：	2024	2025年市場規模：	93.4億美元
歷史數據時期：	2020年至2024年	預測期：	2025年至2032年
預測期（2025-2032年）複合年成長率：	14.30%	預計2032年價值：	238.1億美元

全球腫瘤血液學檢測市場是更廣泛的腫瘤診斷領域中一個具有變革意義的細分市場，從根本上改變了現代醫療保健中癌症檢測、監測和治療決策的方式。

腫瘤血液檢測，也稱為液態生物檢體，是一系列創新的非侵入性診斷技術，用於分析周邊血液樣本中存在的循環性腫瘤細胞(CTC)、循環腫瘤 DNA (ctDNA)、外泌體和其他腫瘤衍生的生物標記。

這項創新技術相比傳統的組織切片檢查具有顯著優勢，包括減輕患者負擔、降低手術風險、實現即時監測以及更全面地捕捉腫瘤異質性。其應用領域廣泛，涵蓋癌症早期篩檢與診斷、治療方案選擇、治療反應監測、微量殘存疾病檢測等。

隨著基因測序技術的進步、人工智慧的融合應用以及越來越多的臨床證據支持液態生物檢體的有效性，腫瘤血液檢測市場正展現出前所未有的成長動能。全球癌症發生率的不斷攀升，以及對精準醫療和個人化治療策略日益成長的需求，正持續推動全球各醫療保健領域的市場擴張。

市場動態

推動全球腫瘤血液學檢測市場快速擴張和臨床應用的主要因素有很多。其中最主要的成長要素是全球癌症負擔的日益惡化。不斷上升的發病率要求提供更有效率、更便捷、更人性化的診斷解決方案，以實現早期發現和整個治療過程中的持續監測。

次世代定序、數位PCR和分子譜分析等技術的進步顯著提高了液態生物檢體的敏感度和特異性，使其日益被視為侵入性組織取樣手術的可行替代方案。隨著精準醫療和個人化治療方案的日益普及，腫瘤血液檢測能夠以前所未有的精確度即時監測治療反應、抗藥性機制和疾病進展，市場成長也進一步加速。然而，目前仍存在一些顯著的局限性，例如先進檢測平台的高成本、許多地區醫保覆蓋範圍有限以及新型診斷技術監管方面的複雜性。

此外，不同醫療體系之間缺乏標準化的通訊協定、品管措施和臨床指南，為實施帶來了挑戰，並可能阻礙其廣泛應用。儘管有這些局限性，但透過在早期癌症篩檢計畫中擴大應用、與人工智慧（AI）和機器學習平台整合以提高診斷準確性以及加大研發投入，仍湧現出巨大的機會。加強製藥公司、診斷設備製造商和醫療機構之間的合作，為市場擴張提供了巨大的潛力，尤其是在傳統切片檢查基礎設施有限但癌症診斷需求持續快速成長的新興經濟體。

本次調查的主要特點

本報告對全球腫瘤血液學檢測市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該研究根據以下參數對全球腫瘤血液學檢測市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球腫瘤血液學檢測市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過各種策略矩陣輕鬆做出決策，這些矩陣用於分析全球腫瘤血液學檢測市場。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

Hoffmann-La Roche Ltd.
Illumina, Inc.
Guardant Health
Bio-Rad Laboratories
Abbott Laboratories
Qiagen
Agilent Technologies
Thermo Fisher Scientific
Siemens Healthineers
GE Healthcare
BD（Becton, Dickinson and Company）
PerkinElmer
Myriad Genetics
Sysmex Corporation
Danaher Corporation

第11章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8830

Tumor Blood Testing Market is estimated to be valued at USD 9.34 Bn in 2025 and is expected to reach USD 23.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.34 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	14.30%	2032 Value Projection:	USD 23.81 Bn

The global tumor blood testing market represents a transformative segment within the broader oncology diagnostics landscape, fundamentally reshaping how cancer detection, monitoring, and treatment decisions are approached in modern healthcare.

Tumor blood testing, also known as liquid biopsy, encompasses a revolutionary array of non-invasive diagnostic techniques that analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other tumor-derived biomarkers present in peripheral blood samples.

This innovative approach offers significant advantages over traditional tissue-based biopsies, including reduced patient discomfort, lower procedural risks, real-time monitoring capabilities, and the ability to capture tumor heterogeneity more comprehensively. The market encompasses various applications ranging from early cancer screening and diagnosis to treatment selection, therapeutic monitoring, and minimal residual disease detection.

With advancing genomic sequencing technologies, artificial intelligence integration, and growing clinical evidence supporting liquid biopsy efficacy, the tumor blood testing market is experiencing unprecedented growth momentum. The increasing prevalence of cancer globally, coupled with rising demand for precision medicine approaches and personalized treatment strategies, continues to drive market expansion across diverse healthcare settings worldwide.

Market Dynamics

The global tumor blood testing market is propelled by several compelling drivers that underscore its rapid expansion and clinical adoption. The primary growth driver stems from the increasing global cancer burden, with rising incidence rates necessitating more efficient, accessible, and patient-friendly diagnostic solutions that can facilitate early detection and continuous monitoring throughout treatment journeys.

Technological advancements in next-generation sequencing, digital PCR, and molecular profiling techniques have significantly enhanced the sensitivity and specificity of liquid biopsies, making them increasingly viable alternatives to invasive tissue sampling procedures. The growing emphasis on precision medicine and personalized treatment approaches further accelerates market growth, as tumor blood testing enables real-time monitoring of treatment response, resistance mechanisms, and disease progression with unprecedented accuracy. However, the market faces notable restraints including high costs associated with advanced testing platforms, limited reimbursement coverage in many regions, and regulatory complexities surrounding novel diagnostic technologies.

Additionally, the lack of standardized protocols, quality control measures, and clinical guidelines across different healthcare systems creates implementation challenges that may hinder widespread adoption. Despite these constraints, substantial opportunities emerge through expanding applications in early-stage cancer screening programs, integration with artificial intelligence and machine learning platforms for enhanced diagnostic accuracy, and growing investments in research and development activities. The increasing collaboration between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions presents significant potential for market expansion, particularly in emerging economies where traditional biopsy infrastructure remains limited but demand for cancer diagnostics continues to grow exponentially.

Key Features of the Study

This report provides in-depth analysis of the global tumor blood testing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tumor blood testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Illumina, Inc., Guardant Health, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Agilent Technologies, Thermo Fisher Scientific, Siemens Healthineers, GE Healthcare, BD (Becton, Dickinson and Company), PerkinElmer, Myriad Genetics, Sysmex Corporation, and Danaher Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global tumor blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor blood testing market

Market Segmentation

Biomarker Type Insights (Revenue, USD Bn, 2020 - 2032)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs) / Exosomes
- Other Cell-Free Nucleic Acids
Technology Insights (Revenue, USD Bn, 2020 - 2032)
- Polymerase Chain Reaction (PCR)-Based Testing
- Next-Generation Sequencing (NGS)
- Microarray-Based Testing
- Mass Spectrometry
- Immunoassays
Clinical Application Insights (Revenue, USD Bn, 2020 - 2032)
- Early Detection/Cancer Screening
- Diagnosis
- Therapy Selection
- Treatment Monitoring
- Minimal Residual Disease (MRD) Detection
- Recurrence Monitoring/Prognosis
Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- GE Healthcare
- BD (Becton, Dickinson and Company)
- PerkinElmer
- Myriad Genetics
- Sysmex Corporation
- Danaher Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Tumor Blood Testing Market, By Biomarker Type
- Global Tumor Blood Testing Market, By Technology
- Global Tumor Blood Testing Market, By Clinical Application
- Global Tumor Blood Testing Market, By Cancer Type
- Global Tumor Blood Testing Market, By End User
- Global Tumor Blood Testing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Tumor Blood Testing Market, By Biomarker Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Circulating Tumor DNA (ctDNA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Circulating Tumor Cells (CTCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Extracellular Vesicles (EVs) / Exosomes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Cell-Free Nucleic Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Tumor Blood Testing Market, By Technology, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Polymerase Chain Reaction (PCR)-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Microarray-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mass Spectrometry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Immunoassays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Tumor Blood Testing Market, By Clinical Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Early Detection/Cancer Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Minimal Residual Disease (MRD) Detection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Recurrence Monitoring/Prognosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Tumor Blood Testing Market, By Cancer Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Tumor Blood Testing Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Tumor Blood Testing Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Qiagen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Agilent Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GE Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BD (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
PerkinElmer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Myriad Genetics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies